Illimis Therapeutics is a biotechnology company developing drug candidates for central nervous system and immune-related diseases. Its core platform, GAIA, is based on TAM (Tyro-3, Axl, and Mertk) receptor biology and is being applied to pipelines including Alzheimer’s disease and immune disorders.